Survival rates for retinoblastoma now approach 100 percent, but in years past, enucleation was the only sure way to cure this rare pediatric malignancy. We're now seeing advances in chemotherapy that not only spare the child's eye, but can preserve vision as well. What makes this chemotherapy regimen so effective, and how can we build on its effectiveness to enhance the vision and the livelihood of children affected by retinoblastoma? Dr. David Abramson, chief of the ophthalmic oncology service at Memorial Sloan-Kettering Cancer Center in New York, joins host Dr. Jennifer Shu to talk about the breadth of retinoblastoma research that has helped us take important strides toward remediation of this disease.
Retinoblastoma Therapy to Save Vision, Rebuilding Lives

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Survival rates for retinoblastoma now approach 100 percent, but in years past, enucleation was the only sure way to cure this rare pediatric malignancy. We're now seeing advances in chemotherapy that not only spare the child's eye, but can preserve vision as well. What makes this chemotherapy regimen so effective, and how can we build on its effectiveness to enhance the vision and the livelihood of children affected by retinoblastoma? Dr. David Abramson, chief of the ophthalmic oncology service at Memorial Sloan-Kettering Cancer Center in New York, joins host Dr. Jennifer Shu to talk about the breadth of retinoblastoma research that has helped us take important strides toward remediation of this disease.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue
Partnering with Patients: Building Effective Communication and Support in HF Care
Clinical Conundrums in ARIA: Differential Diagnoses and Potential Pitfalls in ARIA Evaluation
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers
Evaluating Sleep Deprivation as a Risk Factor for Postpartum Depression
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?